Scientific article
Open access

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia

Published inOncotarget, vol. 7, no. 38, p. 62377-62385
Publication date2016-08-22

CD81 is a cell surface protein which belongs to the tetraspanin family. While in multiple myeloma its expression on plasma cells is associated with worse prognosis, this has not yet been explored in acute myeloid leukemia (AML). We measured membrane expression of CD81 on AML cells at diagnosis, evaluated its association with AML characteristics and its influence on patient outcome after intensive chemotherapy in a cohort of 134 patients. CD81 was detected in 92/134 (69%) patients. Patients with AML expressing CD81 had elevated leukocyte count (P=0.02) and were more likely classified as intermediate or adverse-risk by cytogenetics (P<0.001). CD81 expression had a negative impact on survival (event-free survival, overall survival and relapse-free survival) in univariate (P<0.001) and in multivariate analyses (P=0.003, 0.002 and <0.001, respectively). CD81 has a negative impact on OS in patients with NPM1 mutation (P=0.01) and in patients ELN-favorable (P=0.002). In conclusion, this cell surface marker may be a new prognostic marker for diagnostic risk classification and a potential therapeutic target for drug development in AML.

  • CD81
  • Acute myeloid leukemia
  • Flow cytometry
  • Prognosis
  • Tetraspanin
Affiliation Not a UNIGE publication
Citation (ISO format)
BOYER, Thomas et al. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. In: Oncotarget, 2016, vol. 7, n° 38, p. 62377–62385. doi: 10.18632/oncotarget.11481
Main files (1)
Article (Published version)
ISSN of the journal1949-2553

Technical informations

Creation03/19/2024 9:09:50 AM
First validation05/23/2024 6:58:10 AM
Update time05/23/2024 6:58:10 AM
Status update05/23/2024 6:58:10 AM
Last indexation05/23/2024 6:58:30 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack